Chemotherapy for the treatment of non-small cell lung cancer can be quite toxic, however, durvalumab after chemotherapy can help manage toxicities while improving overall survival, according to the PACFIC trial.
Jamie E. Chaft, MD
Advertisement
Jamie Chaft, MD, specializes in medical oncology, with a special focus on lung cancer. She practices primarily in New York, NY, and is affiliated with Memorial Sloan Kettering Cancer Center.
Articles by Jamie E. Chaft, MD
Jamie E. Chaft, MD, discusses biomarkers used to identify patients with lung cancer who would benefit from immunotherapy and the possibility for future biomarkers in this setting.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
